硫氧还蛋白还原酶：一种新型有效的胃癌化疗疗效监测标志物

胃癌是国际上发病率较高的肿瘤，寻找新型有效的肿瘤标志物用于胃癌的诊断和疗效评估，对于胃癌的临床治疗有较大的帮助。本研究选取经临床确诊的155例胃癌患者为研究对象，探究血浆硫氧还蛋白还原酶（thioredoxin reductase, TR）在胃癌化疗后临床获益人群与未获益人群中检测水平的差异，以及其与治疗效果的关系。结果显示，未获益组TR阳性率为82.67%，显著高于获益组TR阳性率（48.94%）。受试者操作特征曲线（receiver operating characteristic curve，ROC）分析显示，未获益组人群与获益组人群的TR活性诊断阈值为8.95 U/mL，ROC曲线下面积（area under the curve，AUC）为0.8423，明显优于常规胃癌标志物癌胚抗原（carcinoembryonic antigen，CEA），肿瘤特异性抗原（cancer antigen，CA）19-9和CA72-4。同时，TR与常规胃癌标志物的联合检测提高阳性检出率至98.49%。TR被认为是一种新型的胃癌临床化疗疗效监测标志物，与临床疗效评价具有较高的一致性。

Thioredoxin Reductase: a New and Effective Biomarker for Monitoring the Efficacy of Chemotherapy in Gastric Cancer

Gastric cancer (GC) is one of the leading malignancies around the world. Identification of novel and efficient biomarkers for evaluation of therapeutic efficiency in GC could improve the therapeutic strategy in future clinical application. In the current study, a total of 155 GC patients were enrolled to evaluate the levels of plasma thioredoxin reductase (TR) activity to confirm its validity and efficacy in the evaluation of GC therapeutic efficiency. In GC patients after chemotherapy, plasma TR activity was remarkably higher in patients with progressive disease or uncontrolled condition (sensitivity 82.67%) as compared with patients with complete or partial response (sensitivity 48.94%) after chemotherapy (P﹤0.001). TR activity displayed the higher efficiency to distinguish between GC patients with two distinct clinical outcomes than carcinoembryonic antigen (CEA), cancer antigen 72-4(CA72-4) and cancer antigen 19-9 (CA19-9), with a cut-off value of 8.95 U/mL and AUC of 0.8423 based on receiver operating characteristic (ROC) analysis. Moreover, combination of TR with other tumor markers (sensitivity 98.49%) was demonstrated to be more effective in the evaluation of GC therapeutic efficiency than individual biomarker. Together, plasma TR activity was identified as a novel and efficient biomarker for the evaluation of therapeutic efficiency in GC.